L-NMMA acetate structure
|
Common Name | L-NMMA acetate | ||
---|---|---|---|---|
CAS Number | 53308-83-1 | Molecular Weight | 248.279 | |
Density | N/A | Boiling Point | 392.7ºC at 760 mmHg | |
Molecular Formula | C9H20N4O4 | Melting Point | 180-190ºC | |
MSDS | Chinese USA | Flash Point | 191.3ºC |
Use of L-NMMA acetateL-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The Ki values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 µM, respectively. |
Name | ng-monomethyl-l-arginine acetate |
---|---|
Synonym | More Synonyms |
Description | L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The Ki values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 µM, respectively. |
---|---|
Related Catalog | |
Target |
Ki: 0.18 µM (nNOS), 0.4 µM (eNOS), 6 µM (iNOS)[1] |
In Vitro | L-NMMA, starting from 100 μM, produces a concentration-dependent inhibition of the evoked relaxations (2Hz); maximal inhibition at 1 mM averaged about 35%. The inhibitory effect of L-NMMA is unchanged by previous incubation with D-arginine while it is prevented by L-arginine (L-Arg). L-NMMA does not affect isoprenaline-induced relaxation[2]. Superfusion of L-NMMA reduces arteriolar diameter and causes dose-dependent increases in arteriolar tone. The onset of action of L-NMMA is nearly immediate. L-NMMA inhibits vasodilator responses to the endothelium-dependent vasodilator ACh but not to the endothelium-independent NP. NE induced dose-related vasoconstriction that is significantly potentiated by L-NMMA[3]. |
Kinase Assay | NOS activity is determined by monitoring the conversion of L-[14C]arginine to [14C]citrulline. For nNOS, reaction mixtures contain, in a final volume of 200 μL, 20 mM Na+ HEPES buffer, pH 7.5, 100 μM EDTA, 2 mM CaCl2, 10 μg/mL calmodulin, 500 μM dithiothreitol, 100 μM THB, 25 μM FAD, 25 μM FMN, 100 μg/mL bovine serum albumin, 20 μM L-[14C]citrulline, 500 PM NADPH, and enzyme. Reaction is initiated by the addition of L-[14C]citrulline; reaction temperature is 25°C. At appropriate times, typically 3.5, 7, and 10.5 min, 50-1.11 portions are removed and added to 200 pl of a stopping solution of 100 mM Na+ HEPES buffer, pH 5.5, containing 5 mM EGTA. Those samples are immediately heated for 1 min in a boiling water bath, chilled, and centrifuged. A portion (225 μL) of the supernatant is fractionated on small Dowex 50 columns. [14C]citrulline is eluted with 2 ml of water and is quantitated by liquid scintillation counting[1]. |
References |
Boiling Point | 392.7ºC at 760 mmHg |
---|---|
Melting Point | 180-190ºC |
Molecular Formula | C9H20N4O4 |
Molecular Weight | 248.279 |
Flash Point | 191.3ºC |
Exact Mass | 248.148453 |
PSA | 148.53000 |
LogP | 0.59500 |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Safety Phrases | 22-24/25 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
HS Code | 29252900 |
Evidence of oxidative stress and mitochondrial respiratory chain dysfunction in an in vitro model of sepsis-induced kidney injury.
Biochim. Biophys. Acta 1837(10) , 1790-800, (2014) To investigate the role of oxidative stress and/or mitochondrial impairment in the occurrence of acute kidney injury (AKI) during sepsis, we developed a sepsis-induced in vitro model using proximal tu... |
|
PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145.
Nat. Commun. 6 , 6428, (2015) The human genome encodes a family of nine protein arginine methyltransferases (PRMT1-9), whose members can catalyse three distinct types of methylation on arginine residues. Here we identify two splic... |
|
Heparin modulation on hepatic nitric oxide synthase in experimental steatohepatitis.
Exp. Ther. Med. 8(5) , 1551-1558, (2014) Nonalcoholic fatty liver disease (NAFLD) is considered to be a hepatic manifestation of metabolic syndrome, and has been etiologically associated with insulin resistance (IR). The histopathology of NA... |
L-NMMA MONOACETATE |
ANO 1020 |
NG-Methyl-L-arginine acetate salt |
H-ARG(ME)-OH ACOH |
NG-Monomethyl-L-arginine monoacetate |
NMMA ACETATE SALT |
Nω-Monomethyl-L-arginine Acetate |
MFCD00069311 |
L-NMMA,ACETATE SALT |
NoMega-MonoMethyl-L-arginine Acetate |
NG-ME-L-ARG,ACOH |
NG-Methylarginine acetate |
Nω-Methyl-L-arginine Acetate |
L-NMMA ACETATE |
NMMA |
L-Ornithine, N-[imino(methylamino)methyl]-, acetate (1:1) |
N-(N-Methylcarbamimidoyl)-L-ornithine acetate (1:1) |
L-NMMA |
Tilarginine acetate |